HOUSTON

休斯顿

,

，

June 26, 2026

2026年6月26日

/PRNewswire/ --

/美通社/ --

Decoy Therapeutics, Inc. (NASDAQ:

Decoy Therapeutics, Inc.（纳斯达克股票代码：

DCOY

诱饵

)

)

(the 'Company' or 'Decoy'), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the 'PIPE'), which is expected to provide approximately $3.5 million in gross proceeds at closing, before deducting placement agent's fees and other financing expenses payable by the Company.

（以下简称“公司”或“Decoy”），一家致力于开创可设计多重抗病毒药物（D-MAVs™）这一全新类别的生物技术公司，今日宣布已与一家专注于医疗保健领域的机构投资者签订证券购买协议，进行一项私募股权投资公开股权融资（即“PIPE”交易）。该交易预计在扣除由公司支付的配售代理费及其他融资费用前，于交割时提供约350万美元的总收益。

The Company intends to use the net proceeds to advance its lead asset into clinical trials..

公司拟将净收益用于推进其核心资产进入临床试验。

The PIPE consists of (i) $3.5 million of upfront gross proceeds at a purchase price of $5.91 per share from the sale of common stock (or pre-funded warrants in lieu thereof), (ii) a milestone-based Series A warrant with potential additional aggregate gross proceeds of approximately $3.5 million if fully exercised following both shareholder approval and the date of filing by the Company of a Clinical Trial Application with the applicable competent regulatory authority in the European Economic Area to commence a Phase 1 clinical trial, (iii) a milestone-based Series B warrant with potential additional aggregate gross proceeds of approximately $7.0 million if fully exercised following both shareholder approval and the Company's receipt of formal written approval from the Medicines and Healthcare products Regulatory Agency to conduct a Phase 2a human challenge trial in the United Kingdom, and (iv) a milestone-based Series C warrant with potential additional aggregate gross proceeds of approximately $7.0 million if fully exercised following both shareholder approval and the Company's public announcement of data from the Company's positive Phase 2a human challenge trial conducted in the United Kingdom.

该私募股权投资（PIPE）由以下部分组成：(i) 以每股5.91美元的价格出售普通股（或替代的预融资认股权证）所获得的350万美元前期总收益；(ii) 一项基于里程碑的A系列认股权证，若在获得股东批准且公司向欧洲经济区相关主管监管机构提交启动1期临床试验的临床试验申请之日后完全行权，可带来约350万美元的潜在额外总收益；(iii) 一项基于里程碑的B系列认股权证，若在获得股东批准且公司收到英国药品和保健品监管局关于开展2a期人体挑战试验的正式书面批准后完全行权，可带来约700万美元的潜在额外总收益；以及 (iv) 一项基于里程碑的C系列认股权证，若在获得股东批准且公司公开宣布其在英国进行的2a期人体挑战试验的阳性数据后完全行权，可带来约700万美元的潜在额外总收益。

The PIPE was priced 'at-the-market' under the rules and regulations of The Nasdaq Stock Market LLC, with each warrant having an exercise price equal to the deal price. The securities to be issued in the PIPE will be subject to applicable restrictions on transfer. The terms of the PIPE were determined through negotiations between the Company and the investors, based on the closing share price on the determination date..

本次私募股权投资（PIPE）根据纳斯达克股票市场有限责任公司（The Nasdaq Stock Market LLC）的规则和规定按“市价”定价，每份认股权证的行权价格等于交易价格。本次私募股权投资中拟发行的证券将受适用的转让限制约束。本次私募股权投资的条款由公司与投资者基于确定日的收盘价协商确定。

The closing of the offering is expected to occur on or about June 29, 2026, subject to the satisfaction of customary closing conditions.

本次发行的交割预计将于2026年6月29日或前后进行，前提是满足惯常的交割条件。

Curvature Securities LLC is acting as the sole placement agent in connection with the PIPE.

Curvature Securities LLC 担任与 PIPE 相关的独家配售代理。

The offer and sale of the foregoing securities is being made in reliance on an exemption from the registration requirement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act'), and/or Regulation D promulgated thereunder, and applicable state securities laws, and the securities have not been and will not initially be registered under the Securities Act, or applicable state securities laws.

前述证券的发售与销售系依据经修订的《1933年证券法》（以下简称“《证券法》”）第4(a)(2)条项下的注册豁免、和/或据此颁布的D条例，以及适用的州证券法律进行；该等证券未曾且最初也不会根据《证券法》或适用的州证券法律办理注册。

Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to the terms of a registration rights agreement entered into with the investor, the Company agreed to file a registration statement with the U.S.

因此，除非依据生效的注册声明或适用《证券法》及相应州证券法律关于注册要求的豁免，否则不得在美国境内发售或出售该等证券。根据与投资者签订的注册权协议条款，公司同意向美国提交注册声明。

Securities and Exchange Commission (the 'SEC') covering the resale of the shares of common stock issued or underlying pre-funded or common warrants issued to the institutional investor no later than 15 calendar days after the closing of the offering and to use commercially reasonable efforts to have the registration statement declared effective within 90 days following the closing of the offering in the event of a 'full review' by the SEC..

证券交易委员会（“SEC”）涵盖向机构投资者发行的普通股股份或预融资权证或普通权证所依据的普通股股份的转售，须在发行结束后不超过15个日历日内提交，并在SEC进行“全面审查”的情况下，尽商业上合理的努力使该注册声明在发行结束后90天内生效。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售要约或购买要约的征求，也不得在任何州或其他司法管辖区进行此类证券的销售，若在该等州或其他司法管辖区，在根据当地证券法完成注册或资格认定之前，此类要约、征求或销售属违法。

About Decoy Therapeutics

关于Decoy Therapeutics

Decoy Therapeutics is a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs), a new category of antivirals engineered to target shared viral mechanisms, enabling a single, adaptable drug to work across multiple viruses. Built on the proprietary IMP(3)ACT™ platform, which combines AI-assisted design and rapid synthesis, Decoy develops peptide antivirals designed to move faster into the clinic and expand what is possible in viral prevention and treatment.

Decoy Therapeutics 是一家生物技术公司，开创性地研发可设计多重抗病毒药物（D-MAVs）。这是一类新型抗病毒药物，旨在靶向病毒共有的机制，使一种单一且可适应的药物能够对多种病毒发挥作用。依托专有的 IMP(3)ACT™ 平台，该平台融合了人工智能辅助设计与快速合成技术，Decoy 致力于开发肽类抗病毒药物，以加速其进入临床研究阶段，并拓展病毒预防与治疗的可能性。

The Company's lead candidates target multiple respiratory viruses, addressing the health and societal burden of viral disease..

该公司的领先候选药物针对多种呼吸道病毒，旨在减轻病毒性疾病对健康和社会造成的负担。

Forward-Looking Statements

前瞻性陈述

This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Decoy, including expected achievement of milestones for its lead asset and future prospects of Decoy. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Decoy, as well as assumptions made by, and information currently available to, management.

本新闻稿包含根据1995年《私人证券诉讼改革法》定义的关于Decoy的“前瞻性陈述”，包括其核心资产预期里程碑的达成以及Decoy的未来前景。这些陈述可能涉及基于Decoy管理层当前的信念以及管理层所作的假设和目前可获得的信息，对未来计划、趋势、事件、经营业绩或财务状况等方面的目标、意图和期望。

Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'can,' 'should,' 'would,' 'expect,' 'anticipate,' 'plan,' 'likely,' 'believe,' 'estimate,' 'project,' 'intend,' and other similar expressions.

前瞻性陈述通常包括具有预测性质的陈述，这些陈述依赖于或提及未来事件或条件，并包含诸如“可能”、“将”、“能够”、“应该”、“会”、“预期”、“预计”、“计划”、“很可能”、“相信”、“估计”、“预测”、“打算”等词语以及其他类似表述。

Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the risk that the Company will not obtain sufficient financing to execute on its business plans and risks related to Decoy's products and development plans, including unanticipated issues with any IND application process and the potential of the IMP(3)ACT platform.

非历史事实的陈述属于前瞻性陈述。前瞻性陈述基于当前的信念和假设，这些信念和假设受风险和不确定性的影响，并不保证未来的表现。由于各种因素，实际结果可能与任何前瞻性陈述中包含的结果存在重大差异，包括但不限于：公司无法获得足够资金以执行其业务计划的风险，以及与Decoy的产品和开发计划相关的风险，包括任何新药临床试验申请（IND）流程中可能出现的前所未见问题，以及IMP(3)ACT平台的潜力。

Readers are urged to carefully review and consider the various disclosures made by the Company in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as revised or supplemented by its Quarterly Reports on Form.

敬请读者仔细审阅并考虑本公司在向美国证券交易委员会（SEC）提交的报告中所作出的各项披露，包括截至2025年12月31日止财政年度的10-K表格年度报告，以及经其季度报告修订或补充的内容。

SOURCE Decoy Therapeutics, Inc

来源：Decoy Therapeutics, Inc

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示